Cargando…
DDR1 inhibition as a new therapeutic strategy for colorectal cancer
The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149912/ https://www.ncbi.nlm.nih.gov/pubmed/30250919 http://dx.doi.org/10.1080/23723556.2018.1465882 |